

# Cheryl Fitzer-Attas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6563080/publications.pdf>

Version: 2024-02-01

34  
papers

2,549  
citations

304743

22  
h-index

434195

31  
g-index

35  
all docs

35  
docs citations

35  
times ranked

3296  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fit-for-Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience. <i>Clinical and Translational Science</i> , 2021, 14, 62-74.	3.1	28
2	Toward eScales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 208-214.	1.5	5
3	Utility of Huntington's Disease Assessments by Disease Stage: Floor/Ceiling Effects. <i>Frontiers in Neurology</i> , 2021, 12, 595679.	2.4	6
4	Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). <i>Npj Digital Medicine</i> , 2020, 3, 55.	10.9	236
5	PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression. <i>Movement Disorders</i> , 2020, 35, 606-615.	3.9	25
6	Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 212-224.	1.5	137
7	Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D 2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18 F-MNI-659 and 11 C-raclopride with correction for partial volume effect. <i>NeuroImage</i> , 2017, 152, 330-339.	4.2	24
8	Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 736-736.	46.4	34
9	[P462]: LANDSCAPE ANALYSIS OF BIOMETRIC MONITORING DEVICES (BMDS) UTILIZED IN ASSESSING COGNITION, SLEEP AND MOBILITY IN ALZHEIMER'S DISEASE AND OTHER AGE-RELATED NEUROLOGICAL DISEASES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1322.	0.8	0
10	Revisiting the Logan plot to account for non-negligible blood volume in brain tissue. <i>EJNMMI Research</i> , 2017, 7, 66.	2.5	8
11	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. <i>Brain</i> , 2016, 139, 2050-2062.	7.6	53
12	Long-term effects of rasagiline and the natural history of treated Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1489-1496.	3.9	45
13	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 145-152.	10.2	90
14	HD-CAB: A cognitive assessment battery for clinical trials in Huntington's disease <sup>1,2,3</sup> . <i>Movement Disorders</i> , 2014, 29, 1281-1288.	3.9	73
15	Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease. <i>PLoS ONE</i> , 2013, 8, e60691.	2.5	33
16	Prerequisites to launch neuroprotective trials in Parkinson's disease: An industry perspective. <i>Movement Disorders</i> , 2012, 27, 651-655.	3.9	20
17	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology</i> , The, 2011, 10, 415-423.	10.2	192
18	High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2011, 118, 1199-1207.	2.8	28

#	ARTICLE	IF	CITATIONS
19	Increased Melanoma Risk in Parkinson Disease. Archives of Neurology, 2010, 67, 347.	4.5	101
20	Long-Term Efficacy of Rasagiline in Early Parkinson's Disease. International Journal of Neuroscience, 2010, 120, 404-408.	1.6	29
21	Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology, 2009, 72, S32-8.	1.1	78
22	Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Movement Disorders, 2009, 24, 564-573.	3.9	126
23	An Attenuated Immune Response Is Sufficient to Enhance Cognition in an Alzheimer's Disease Mouse Model Immunized with Amyloid- $\beta$ Derivatives. Journal of Neuroscience, 2004, 24, 6277-6282.	3.6	162
24	The Role of Platelet Derived Growth Factor (PDGF) and Its Receptors in Cancer and Metastasis. , 2001, , 167-186.		0
25	Fc $\gamma$ Receptor-Mediated Phagocytosis in Macrophages Lacking the Src Family Tyrosine Kinases Hck, Fgr, and Lyn. Journal of Experimental Medicine, 2000, 191, 669-682.	8.5	255
26	Tyrosine kinase chimeras for antigen-selective T-body therapy. Advanced Drug Delivery Reviews, 1998, 31, 171-182.	13.7	14
27	A Critical Role for Syk in Signal Transduction and Phagocytosis Mediated by Fc $\gamma$ Receptors on Macrophages. Journal of Experimental Medicine, 1997, 186, 1027-1039.	8.5	471
28	Direct T Cell Activation by Chimeric Single Chain Fv-Syk Promotes Syk-Cbl Association and Cbl Phosphorylation. Journal of Biological Chemistry, 1997, 272, 8551-8557.	3.4	31
29	The T-body approach: potential for cancer immunotherapy. Seminars in Immunopathology, 1996, 18, 199-209.	4.0	73
30	The expression of PDGF- $\beta$ but not PDGF- $\alpha$ receptors is suppressed in Swiss/3T3 fibroblasts over-expressing protein kinase C- $\beta$ . FEBS Letters, 1994, 342, 165-170.	2.8	5
31	Expression of functionally intact pdgf- $\beta$ receptors in highly metastatic 3ll lewis lung carcinoma cells. International Journal of Cancer, 1993, 53, 315-322.	5.1	14
32	Genes and Antigens Controlling Tumor Metastasis. Contributions To Oncology / Beitrage Zur Onkologie, 1992, , 1-12.	0.1	0
33	Studies on Protein Kinase C and Colon Carcinogenesis. Archives of Surgery, 1987, 122, 1475.	2.2	42
34	The regulation of protein kinase C by chenodeoxycholate, deoxycholate and several structurally related bile acids. Carcinogenesis, 1987, 8, 217-220.	2.8	108